Page last updated: 2024-10-15

hesperadin

Cross-References

ID SourceID
PubMed CID135421442
CHEMBL ID514409
CHEBI ID70726
SCHEMBL ID1116351
SCHEMBL ID1116356
MeSH IDM0450517

Synonyms (45)

Synonym
HY-12054
(z)-n-(2-oxo-3-(phenyl(4-(piperidin-1-ylmethyl)phenylamino)methylene)indolin-5-yl)ethanesulfonamide
hesperadin ,
TCMDC-135395 ,
chebi:70726 ,
CHEMBL514409 ,
422513-13-1
NCGC00346542-01
n-[(3z)-2-oxo-3-(phenyl{[4-(piperidin-1-ylmethyl)phenyl]amino}methylidene)-2,3-dihydro-1h-indol-5-yl]ethanesulfonamide
CS-0213
hesperadine
S1529
n-[2,3-dihydro-2-oxo-3-[(3z)-phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1h-indol-5-yl]ethanesulfonamide
1265801-59-9
MLS006011039
smr004702832
unii-ptr491os14
ethanesulfonamide, n-(2,3-dihydro-2-oxo-3-((3z)-phenyl((4-(1-piperidinylmethyl)phenyl)amino)methylene)-1h-indol-5-yl)-
ptr491os14 ,
SCHEMBL1116351
SCHEMBL1116356
n-[(3z)-2-oxo-3-[phenyl-[[4-(piperidin-1-ylmethyl)phenyl]amino]methylidene]-1h-indol-5-yl]ethanesulfonamide
gtpl8354
(z)-n-(2-oxo-3-(phenyl((4-(piperidin-1-ylmethyl)phenyl)amino)methylene)indolin-5-yl)ethanesulfonamide
bdbm192753
AKOS025404841
J-523310
DTXSID00195086
AKOS030243077
HMS3654N20
mfcd18074526
n-{(3z)-2-oxo-3-[phenyl({4-[(piperidin-1-yl)methyl]phenyl}amino)methylidene]-2,3-dihydro-1h-indol-5-yl}ethanesulfonamide
fe7 ,
n-[2-hydroxy-3-[c-phenyl-n-[4-(piperidin-1-ylmethyl)phenyl]carbonimidoyl]-1h-indol-5-yl]ethanesulfonamide
SW219406-1
FT-0771055
Q5745805
AS-35163
BCP02222
SB19304
CCG-269827
EX-A2067
n-[(3z)-2-oxo-3-[phenyl-[4-(piperidin-1-ylmethyl)anilino]methylidene]-1h-indol-5-yl]ethanesulfonamide
NCGC00346542-10
AC-35920

Treatment

Hesperadin treatment increased the ratio of metaphase cells. The ratio of anaphase/telophase cells decreased. The mitotic index was not affected in Hesperadin-treated cells.

ExcerptReference
"Hesperadin treatment induced the delay of CenH3 alignment on the spindle equator."( Live cell imaging reveals plant aurora kinase has dual roles during mitosis.
Fukui, K; Kurihara, D; Matsunaga, S; Uchiyama, S, 2008
)
"Hesperadin treatment increased the ratio of metaphase cells, while the ratio of anaphase/telophase cells decreased, although the mitotic index was not affected in Hesperadin-treated cells."( Aurora kinase is required for chromosome segregation in tobacco BY-2 cells.
Fujimoto, S; Fukui, K; Kawabe, A; Kurihara, D; Matsunaga, S; Noda, M; Uchiyama, S, 2006
)

Bioavailability

ExcerptReference
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (24)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fumarate hydrataseHomo sapiens (human)Potency18.65480.00308.794948.0869AID1347053
PPM1D proteinHomo sapiens (human)Potency2.62120.00529.466132.9993AID1347411
EWS/FLI fusion proteinHomo sapiens (human)Potency0.24010.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
polyproteinZika virusPotency18.65480.00308.794948.0869AID1347053
Interferon betaHomo sapiens (human)Potency2.62120.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Aurora kinase AHomo sapiens (human)IC50 (µMol)0.01100.00000.46208.6000AID706704
Glucose transporterLeishmania mexicanaIC50 (µMol)1.11400.08102.30676.7450AID1207598
Serine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)IC50 (µMol)0.78000.04532.28609.9390AID1801919
Hexose transporter 1 Plasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)1.34400.09002.22205.8850AID1207597
Solute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)IC50 (µMol)1.43400.00492.99549.9920AID1207599
Maternal embryonic leucine zipper kinaseHomo sapiens (human)IC50 (µMol)0.22500.00040.35770.7600AID1474637
Aurora kinase B-AXenopus laevis (African clawed frog)IC50 (µMol)0.00300.00300.02230.0450AID706705
Aurora kinase BHomo sapiens (human)IC50 (µMol)0.20060.00030.96349.8000AID1741600; AID1876004; AID273715; AID353620; AID706706
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Ribosomal protein S6 kinase alpha-5Homo sapiens (human)Kd0.03100.01701.973729.9570AID389045
Ribosomal protein S6 kinase alpha-4Homo sapiens (human)Kd0.09400.01201.63967.2000AID389046
Tyrosine-protein kinase Fes/FpsHomo sapiens (human)Kd0.14900.00481.09867.4000AID389051
Proto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)Kd0.07700.00051.17415.8000AID389053
Leukocyte tyrosine kinase receptorHomo sapiens (human)Kd0.05200.00102.06317.5000AID389052
Non-receptor tyrosine-protein kinase TYK2Homo sapiens (human)Kd0.07500.00091.55758.7000AID389056
Focal adhesion kinase 1Homo sapiens (human)Kd0.03300.00051.225513.0390AID389054
5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)Kd0.01900.00371.891315.3890AID389047
Serine/threonine-protein kinase PAK 2Homo sapiens (human)Kd14.00000.00312.30456.0000AID389050
Protein-tyrosine kinase 2-betaHomo sapiens (human)Kd0.01000.00111.945030.4140AID389055
Serine/threonine-protein kinase BRSK2Homo sapiens (human)Kd0.09200.00351.98638.9000AID389048
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (368)

Processvia Protein(s)Taxonomy
protein phosphorylationAurora kinase AHomo sapiens (human)
response to woundingAurora kinase AHomo sapiens (human)
liver regenerationAurora kinase AHomo sapiens (human)
G2/M transition of mitotic cell cycleAurora kinase AHomo sapiens (human)
mitotic cell cycleAurora kinase AHomo sapiens (human)
chromatin remodelingAurora kinase AHomo sapiens (human)
protein phosphorylationAurora kinase AHomo sapiens (human)
apoptotic processAurora kinase AHomo sapiens (human)
spindle organizationAurora kinase AHomo sapiens (human)
spindle assembly involved in female meiosis IAurora kinase AHomo sapiens (human)
mitotic centrosome separationAurora kinase AHomo sapiens (human)
anterior/posterior axis specificationAurora kinase AHomo sapiens (human)
regulation of G2/M transition of mitotic cell cycleAurora kinase AHomo sapiens (human)
negative regulation of gene expressionAurora kinase AHomo sapiens (human)
peptidyl-serine phosphorylationAurora kinase AHomo sapiens (human)
regulation of protein stabilityAurora kinase AHomo sapiens (human)
negative regulation of protein bindingAurora kinase AHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processAurora kinase AHomo sapiens (human)
negative regulation of apoptotic processAurora kinase AHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processAurora kinase AHomo sapiens (human)
positive regulation of mitotic nuclear divisionAurora kinase AHomo sapiens (human)
positive regulation of mitotic cell cycleAurora kinase AHomo sapiens (human)
regulation of centrosome cycleAurora kinase AHomo sapiens (human)
protein autophosphorylationAurora kinase AHomo sapiens (human)
cell divisionAurora kinase AHomo sapiens (human)
centrosome localizationAurora kinase AHomo sapiens (human)
cilium disassemblyAurora kinase AHomo sapiens (human)
protein localization to centrosomeAurora kinase AHomo sapiens (human)
positive regulation of mitochondrial fissionAurora kinase AHomo sapiens (human)
positive regulation of oocyte maturationAurora kinase AHomo sapiens (human)
regulation of signal transduction by p53 class mediatorAurora kinase AHomo sapiens (human)
neuron projection extensionAurora kinase AHomo sapiens (human)
mitotic spindle organizationAurora kinase AHomo sapiens (human)
regulation of cytokinesisAurora kinase AHomo sapiens (human)
endothelial cell proliferationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
mRNA catabolic processSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
regulation of macroautophagySerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
positive regulation of RNA splicingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
cellular response to unfolded proteinSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
response to endoplasmic reticulum stressSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
peptidyl-serine autophosphorylationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
IRE1-mediated unfolded protein responseSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
positive regulation of JUN kinase activitySerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
mRNA splicing, via endonucleolytic cleavage and ligationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
cellular response to hydrogen peroxideSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
cellular response to glucose stimulusSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
positive regulation of endoplasmic reticulum unfolded protein responseSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
insulin metabolic processSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
peptidyl-serine trans-autophosphorylationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
negative regulation of cytokine productionRibosomal protein S6 kinase alpha-5Homo sapiens (human)
chromatin remodelingRibosomal protein S6 kinase alpha-5Homo sapiens (human)
regulation of DNA-templated transcriptionRibosomal protein S6 kinase alpha-5Homo sapiens (human)
protein phosphorylationRibosomal protein S6 kinase alpha-5Homo sapiens (human)
inflammatory responseRibosomal protein S6 kinase alpha-5Homo sapiens (human)
axon guidanceRibosomal protein S6 kinase alpha-5Homo sapiens (human)
positive regulation of CREB transcription factor activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
intracellular signal transductionRibosomal protein S6 kinase alpha-5Homo sapiens (human)
post-translational protein modificationRibosomal protein S6 kinase alpha-5Homo sapiens (human)
negative regulation of DNA-templated transcriptionRibosomal protein S6 kinase alpha-5Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIRibosomal protein S6 kinase alpha-5Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
interleukin-1-mediated signaling pathwayRibosomal protein S6 kinase alpha-5Homo sapiens (human)
regulation of postsynapse organizationRibosomal protein S6 kinase alpha-5Homo sapiens (human)
peptidyl-serine phosphorylationRibosomal protein S6 kinase alpha-5Homo sapiens (human)
negative regulation of cytokine productionRibosomal protein S6 kinase alpha-4Homo sapiens (human)
chromatin remodelingRibosomal protein S6 kinase alpha-4Homo sapiens (human)
regulation of DNA-templated transcriptionRibosomal protein S6 kinase alpha-4Homo sapiens (human)
protein phosphorylationRibosomal protein S6 kinase alpha-4Homo sapiens (human)
inflammatory responseRibosomal protein S6 kinase alpha-4Homo sapiens (human)
positive regulation of CREB transcription factor activityRibosomal protein S6 kinase alpha-4Homo sapiens (human)
intracellular signal transductionRibosomal protein S6 kinase alpha-4Homo sapiens (human)
post-translational protein modificationRibosomal protein S6 kinase alpha-4Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIRibosomal protein S6 kinase alpha-4Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityRibosomal protein S6 kinase alpha-4Homo sapiens (human)
interleukin-1-mediated signaling pathwayRibosomal protein S6 kinase alpha-4Homo sapiens (human)
peptidyl-serine phosphorylationRibosomal protein S6 kinase alpha-4Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
microtubule bundle formationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
centrosome cycleTyrosine-protein kinase Fes/FpsHomo sapiens (human)
regulation of cell shapeTyrosine-protein kinase Fes/FpsHomo sapiens (human)
positive regulation of neuron projection developmentTyrosine-protein kinase Fes/FpsHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
regulation of cell adhesionTyrosine-protein kinase Fes/FpsHomo sapiens (human)
positive regulation of microtubule polymerizationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
regulation of cell population proliferationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
regulation of mast cell degranulationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
regulation of cell differentiationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
positive regulation of myeloid cell differentiationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
positive regulation of monocyte differentiationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
protein autophosphorylationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
myoblast proliferationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
cardiac muscle cell proliferationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
regulation of vesicle-mediated transportTyrosine-protein kinase Fes/FpsHomo sapiens (human)
cellular response to vitamin DTyrosine-protein kinase Fes/FpsHomo sapiens (human)
regulation of cell motilityTyrosine-protein kinase Fes/FpsHomo sapiens (human)
chemotaxisTyrosine-protein kinase Fes/FpsHomo sapiens (human)
cell adhesionTyrosine-protein kinase Fes/FpsHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
regulation of cell growthProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
columnar/cuboidal epithelial cell developmentProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
protein phosphorylationProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
spermatogenesisProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
cell differentiationProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
regulation of TOR signalingProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
positive regulation of kinase activityProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
multicellular organism developmentProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
central nervous system developmentSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to hypoxiaSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
female pregnancySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
long-chain fatty acid import across plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
L-ascorbic acid metabolic processSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cerebral cortex developmentSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cellular response to glucose starvationSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
xenobiotic transportSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
photoreceptor cell maintenanceSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
protein-containing complex assemblySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cellular response to mechanical stimulusSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cellular hyperosmotic responseSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose import across plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to Thyroglobulin triiodothyronineSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transmembrane transportSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose importSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to insulinSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
dehydroascorbic acid transportSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
protein phosphorylationLeukocyte tyrosine kinase receptorHomo sapiens (human)
signal transductionLeukocyte tyrosine kinase receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayLeukocyte tyrosine kinase receptorHomo sapiens (human)
cell population proliferationLeukocyte tyrosine kinase receptorHomo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processLeukocyte tyrosine kinase receptorHomo sapiens (human)
positive regulation of neuron projection developmentLeukocyte tyrosine kinase receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationLeukocyte tyrosine kinase receptorHomo sapiens (human)
negative regulation of apoptotic processLeukocyte tyrosine kinase receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionLeukocyte tyrosine kinase receptorHomo sapiens (human)
cellular response to retinoic acidLeukocyte tyrosine kinase receptorHomo sapiens (human)
regulation of cell population proliferationLeukocyte tyrosine kinase receptorHomo sapiens (human)
positive regulation of kinase activityLeukocyte tyrosine kinase receptorHomo sapiens (human)
regulation of neuron differentiationLeukocyte tyrosine kinase receptorHomo sapiens (human)
multicellular organism developmentLeukocyte tyrosine kinase receptorHomo sapiens (human)
protein phosphorylationNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
immune responseNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cytokine-mediated signaling pathwayNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of type II interferon productionNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of interleukin-17 productionNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of natural killer cell proliferationNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
interleukin-12-mediated signaling pathwayNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
type III interferon-mediated signaling pathwayNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of T cell proliferationNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of NK T cell proliferationNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
type II interferon-mediated signaling pathwayNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
type I interferon-mediated signaling pathwayNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cellular response to virusNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
interleukin-10-mediated signaling pathwayNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of protein localization to nucleusNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of T-helper 17 type immune responseNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
intracellular signal transductionNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cell differentiationNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of macrophage chemotaxisFocal adhesion kinase 1Homo sapiens (human)
positive regulation of macrophage proliferationFocal adhesion kinase 1Homo sapiens (human)
angiogenesisFocal adhesion kinase 1Homo sapiens (human)
placenta developmentFocal adhesion kinase 1Homo sapiens (human)
regulation of protein phosphorylationFocal adhesion kinase 1Homo sapiens (human)
positive regulation of protein phosphorylationFocal adhesion kinase 1Homo sapiens (human)
heart morphogenesisFocal adhesion kinase 1Homo sapiens (human)
signal complex assemblyFocal adhesion kinase 1Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayFocal adhesion kinase 1Homo sapiens (human)
integrin-mediated signaling pathwayFocal adhesion kinase 1Homo sapiens (human)
axon guidanceFocal adhesion kinase 1Homo sapiens (human)
positive regulation of cell population proliferationFocal adhesion kinase 1Homo sapiens (human)
regulation of cell shapeFocal adhesion kinase 1Homo sapiens (human)
regulation of endothelial cell migrationFocal adhesion kinase 1Homo sapiens (human)
regulation of epithelial cell migrationFocal adhesion kinase 1Homo sapiens (human)
positive regulation of epithelial cell migrationFocal adhesion kinase 1Homo sapiens (human)
positive regulation of epithelial to mesenchymal transitionFocal adhesion kinase 1Homo sapiens (human)
positive regulation of fibroblast migrationFocal adhesion kinase 1Homo sapiens (human)
cell migrationFocal adhesion kinase 1Homo sapiens (human)
peptidyl-tyrosine phosphorylationFocal adhesion kinase 1Homo sapiens (human)
negative regulation of cell-cell adhesionFocal adhesion kinase 1Homo sapiens (human)
establishment of cell polarityFocal adhesion kinase 1Homo sapiens (human)
positive regulation of cell migrationFocal adhesion kinase 1Homo sapiens (human)
regulation of cell adhesion mediated by integrinFocal adhesion kinase 1Homo sapiens (human)
detection of muscle stretchFocal adhesion kinase 1Homo sapiens (human)
netrin-activated signaling pathwayFocal adhesion kinase 1Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisFocal adhesion kinase 1Homo sapiens (human)
regulation of cell population proliferationFocal adhesion kinase 1Homo sapiens (human)
negative regulation of apoptotic processFocal adhesion kinase 1Homo sapiens (human)
regulation of GTPase activityFocal adhesion kinase 1Homo sapiens (human)
regulation of osteoblast differentiationFocal adhesion kinase 1Homo sapiens (human)
positive regulation of protein kinase activityFocal adhesion kinase 1Homo sapiens (human)
protein autophosphorylationFocal adhesion kinase 1Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayFocal adhesion kinase 1Homo sapiens (human)
ephrin receptor signaling pathwayFocal adhesion kinase 1Homo sapiens (human)
cell motilityFocal adhesion kinase 1Homo sapiens (human)
regulation of cytoskeleton organizationFocal adhesion kinase 1Homo sapiens (human)
regulation of focal adhesion assemblyFocal adhesion kinase 1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionFocal adhesion kinase 1Homo sapiens (human)
growth hormone receptor signaling pathwayFocal adhesion kinase 1Homo sapiens (human)
positive regulation of wound healingFocal adhesion kinase 1Homo sapiens (human)
regulation of substrate adhesion-dependent cell spreadingFocal adhesion kinase 1Homo sapiens (human)
positive regulation of ubiquitin-dependent protein catabolic processFocal adhesion kinase 1Homo sapiens (human)
negative regulation of anoikisFocal adhesion kinase 1Homo sapiens (human)
protein phosphorylationFocal adhesion kinase 1Homo sapiens (human)
epidermal growth factor receptor signaling pathwayFocal adhesion kinase 1Homo sapiens (human)
regulation of cell adhesionFocal adhesion kinase 1Homo sapiens (human)
lipid droplet disassembly5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to hypoxia5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
glucose metabolic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
chromatin remodeling5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein phosphorylation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
fatty acid biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cholesterol biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
autophagy5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
signal transduction5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of cell population proliferation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
lipid biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to UV5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cold acclimation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to gamma radiation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of autophagy5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of gene expression5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of gene expression5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
bile acid and bile salt transport5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
Wnt signaling pathway5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
fatty acid oxidation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to caffeine5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to nutrient levels5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of TOR signaling5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
regulation of peptidyl-serine phosphorylation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to oxidative stress5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
bile acid signaling pathway5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to glucose starvation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
glucose homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
regulation of circadian rhythm5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of apoptotic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to estrogen5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of cholesterol biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of glycolytic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of DNA-templated transcription5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of glucosylceramide biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of insulin receptor signaling pathway5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
rhythmic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of skeletal muscle tissue development5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of lipid catabolic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
fatty acid homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
regulation of vesicle-mediated transport5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
motor behavior5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
CAMKK-AMPK signaling cascade5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
regulation of stress granule assembly5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
neuron cellular homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to hydrogen peroxide5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
regulation of microtubule cytoskeleton organization5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to calcium ion5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to glucose stimulus5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to ethanol5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to prostaglandin E stimulus5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to organonitrogen compound5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to hypoxia5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to xenobiotic stimulus5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
energy homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
regulation of bile acid secretion5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of mitochondrial transcription5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of protein localization5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of hepatocyte apoptotic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of protein targeting to mitochondrion5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of adipose tissue development5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of TORC1 signaling5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of tubulin deacetylation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein localization to lipid droplet5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of peptidyl-lysine acetylation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase PAK 2Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathwaySerine/threonine-protein kinase PAK 2Homo sapiens (human)
cardiac muscle hypertrophySerine/threonine-protein kinase PAK 2Homo sapiens (human)
negative regulation of protein kinase activitySerine/threonine-protein kinase PAK 2Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase PAK 2Homo sapiens (human)
signal transductionSerine/threonine-protein kinase PAK 2Homo sapiens (human)
phosphorylationSerine/threonine-protein kinase PAK 2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase PAK 2Homo sapiens (human)
adherens junction assemblySerine/threonine-protein kinase PAK 2Homo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase PAK 2Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwaySerine/threonine-protein kinase PAK 2Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationSerine/threonine-protein kinase PAK 2Homo sapiens (human)
regulation of cytoskeleton organizationSerine/threonine-protein kinase PAK 2Homo sapiens (human)
negative regulation of stress fiber assemblySerine/threonine-protein kinase PAK 2Homo sapiens (human)
dendritic spine developmentSerine/threonine-protein kinase PAK 2Homo sapiens (human)
bicellular tight junction assemblySerine/threonine-protein kinase PAK 2Homo sapiens (human)
cellular response to organic cyclic compoundSerine/threonine-protein kinase PAK 2Homo sapiens (human)
cellular response to transforming growth factor beta stimulusSerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein localization to cell-cell junctionSerine/threonine-protein kinase PAK 2Homo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathwaySerine/threonine-protein kinase PAK 2Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in execution phase of apoptosisSerine/threonine-protein kinase PAK 2Homo sapiens (human)
regulation of axonogenesisSerine/threonine-protein kinase PAK 2Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PAK 2Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase PAK 2Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProtein-tyrosine kinase 2-betaHomo sapiens (human)
MAPK cascadeProtein-tyrosine kinase 2-betaHomo sapiens (human)
oocyte maturationProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to hypoxiaProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of cell-matrix adhesionProtein-tyrosine kinase 2-betaHomo sapiens (human)
sprouting angiogenesisProtein-tyrosine kinase 2-betaHomo sapiens (human)
adaptive immune responseProtein-tyrosine kinase 2-betaHomo sapiens (human)
marginal zone B cell differentiationProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to ischemiaProtein-tyrosine kinase 2-betaHomo sapiens (human)
protein phosphorylationProtein-tyrosine kinase 2-betaHomo sapiens (human)
apoptotic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
cellular defense responseProtein-tyrosine kinase 2-betaHomo sapiens (human)
signal transductionProtein-tyrosine kinase 2-betaHomo sapiens (human)
cell surface receptor signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
signal complex assemblyProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationProtein-tyrosine kinase 2-betaHomo sapiens (human)
integrin-mediated signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of cell population proliferationProtein-tyrosine kinase 2-betaHomo sapiens (human)
negative regulation of cell population proliferationProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of cell shapeProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to xenobiotic stimulusProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to mechanical stimulusProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to hormoneProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to glucoseProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of endothelial cell migrationProtein-tyrosine kinase 2-betaHomo sapiens (human)
negative regulation of muscle cell apoptotic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of macrophage chemotaxisProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of neuron projection developmentProtein-tyrosine kinase 2-betaHomo sapiens (human)
glial cell proliferationProtein-tyrosine kinase 2-betaHomo sapiens (human)
peptidyl-tyrosine phosphorylationProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of cell adhesionProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of cell growthProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of cell migrationProtein-tyrosine kinase 2-betaHomo sapiens (human)
negative regulation of bone mineralizationProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of actin filament polymerizationProtein-tyrosine kinase 2-betaHomo sapiens (human)
cortical cytoskeleton organizationProtein-tyrosine kinase 2-betaHomo sapiens (human)
neuron projection developmentProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of actin cytoskeleton organizationProtein-tyrosine kinase 2-betaHomo sapiens (human)
tumor necrosis factor-mediated signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to immobilization stressProtein-tyrosine kinase 2-betaHomo sapiens (human)
peptidyl-tyrosine autophosphorylationProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to cocaineProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to hydrogen peroxideProtein-tyrosine kinase 2-betaHomo sapiens (human)
activation of Janus kinase activityProtein-tyrosine kinase 2-betaHomo sapiens (human)
negative regulation of apoptotic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
stress fiber assemblyProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to cation stressProtein-tyrosine kinase 2-betaHomo sapiens (human)
negative regulation of potassium ion transportProtein-tyrosine kinase 2-betaHomo sapiens (human)
negative regulation of neuron apoptotic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
blood vessel endothelial cell migrationProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of nitric oxide biosynthetic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
bone resorptionProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to ethanolProtein-tyrosine kinase 2-betaHomo sapiens (human)
negative regulation of myeloid cell differentiationProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of translationProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of angiogenesisProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of protein kinase activityProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of JNK cascadeProtein-tyrosine kinase 2-betaHomo sapiens (human)
protein autophosphorylationProtein-tyrosine kinase 2-betaHomo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
focal adhesion assemblyProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of synaptic plasticityProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of release of sequestered calcium ion into cytosolProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to cAMPProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to calcium ionProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProtein-tyrosine kinase 2-betaHomo sapiens (human)
long-term synaptic potentiationProtein-tyrosine kinase 2-betaHomo sapiens (human)
long-term synaptic depressionProtein-tyrosine kinase 2-betaHomo sapiens (human)
protein-containing complex assemblyProtein-tyrosine kinase 2-betaHomo sapiens (human)
chemokine-mediated signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeProtein-tyrosine kinase 2-betaHomo sapiens (human)
cellular response to retinoic acidProtein-tyrosine kinase 2-betaHomo sapiens (human)
cellular response to fluid shear stressProtein-tyrosine kinase 2-betaHomo sapiens (human)
endothelin receptor signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of postsynaptic density assemblyProtein-tyrosine kinase 2-betaHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of ubiquitin-dependent protein catabolic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of ubiquitin-dependent protein catabolic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of B cell chemotaxisProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of DNA biosynthetic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
epidermal growth factor receptor signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
G2/M transition of mitotic cell cycleMaternal embryonic leucine zipper kinaseHomo sapiens (human)
apoptotic processMaternal embryonic leucine zipper kinaseHomo sapiens (human)
cell population proliferationMaternal embryonic leucine zipper kinaseHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressMaternal embryonic leucine zipper kinaseHomo sapiens (human)
hemopoiesisMaternal embryonic leucine zipper kinaseHomo sapiens (human)
positive regulation of apoptotic processMaternal embryonic leucine zipper kinaseHomo sapiens (human)
protein autophosphorylationMaternal embryonic leucine zipper kinaseHomo sapiens (human)
neural precursor cell proliferationMaternal embryonic leucine zipper kinaseHomo sapiens (human)
protein phosphorylationMaternal embryonic leucine zipper kinaseHomo sapiens (human)
G2/M transition of mitotic cell cycleSerine/threonine-protein kinase BRSK2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase BRSK2Homo sapiens (human)
exocytosisSerine/threonine-protein kinase BRSK2Homo sapiens (human)
axonogenesisSerine/threonine-protein kinase BRSK2Homo sapiens (human)
regulation of neuron projection developmentSerine/threonine-protein kinase BRSK2Homo sapiens (human)
establishment of cell polaritySerine/threonine-protein kinase BRSK2Homo sapiens (human)
actin cytoskeleton organizationSerine/threonine-protein kinase BRSK2Homo sapiens (human)
neuron differentiationSerine/threonine-protein kinase BRSK2Homo sapiens (human)
ERAD pathwaySerine/threonine-protein kinase BRSK2Homo sapiens (human)
regulation of ATP-dependent activitySerine/threonine-protein kinase BRSK2Homo sapiens (human)
regulation of axonogenesisSerine/threonine-protein kinase BRSK2Homo sapiens (human)
cell divisionSerine/threonine-protein kinase BRSK2Homo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusSerine/threonine-protein kinase BRSK2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressSerine/threonine-protein kinase BRSK2Homo sapiens (human)
microtubule cytoskeleton organization involved in establishment of planar polaritySerine/threonine-protein kinase BRSK2Homo sapiens (human)
regulation of retrograde protein transport, ER to cytosolSerine/threonine-protein kinase BRSK2Homo sapiens (human)
regulation of synaptic vesicle clusteringSerine/threonine-protein kinase BRSK2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIAurora kinase BHomo sapiens (human)
mitotic cell cycleAurora kinase BHomo sapiens (human)
mitotic cytokinesisAurora kinase BHomo sapiens (human)
negative regulation of B cell apoptotic processAurora kinase BHomo sapiens (human)
protein phosphorylationAurora kinase BHomo sapiens (human)
spindle organizationAurora kinase BHomo sapiens (human)
attachment of spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
abscissionAurora kinase BHomo sapiens (human)
negative regulation of protein bindingAurora kinase BHomo sapiens (human)
positive regulation of telomere maintenance via telomeraseAurora kinase BHomo sapiens (human)
negative regulation of cytokinesisAurora kinase BHomo sapiens (human)
positive regulation of cytokinesisAurora kinase BHomo sapiens (human)
protein localization to kinetochoreAurora kinase BHomo sapiens (human)
cellular response to UVAurora kinase BHomo sapiens (human)
cleavage furrow formationAurora kinase BHomo sapiens (human)
post-translational protein modificationAurora kinase BHomo sapiens (human)
cell cycle G2/M phase transitionAurora kinase BHomo sapiens (human)
mitotic cytokinesis checkpoint signalingAurora kinase BHomo sapiens (human)
negative regulation of innate immune responseAurora kinase BHomo sapiens (human)
protein autophosphorylationAurora kinase BHomo sapiens (human)
mitotic spindle midzone assemblyAurora kinase BHomo sapiens (human)
positive regulation of telomerase activityAurora kinase BHomo sapiens (human)
regulation of chromosome segregationAurora kinase BHomo sapiens (human)
positive regulation of mitotic sister chromatid segregationAurora kinase BHomo sapiens (human)
positive regulation of mitotic cell cycle spindle assembly checkpointAurora kinase BHomo sapiens (human)
mitotic spindle assemblyAurora kinase BHomo sapiens (human)
negative regulation of cGAS/STING signaling pathwayAurora kinase BHomo sapiens (human)
regulation of signal transduction by p53 class mediatorAurora kinase BHomo sapiens (human)
positive regulation of mitotic sister chromatid separationAurora kinase BHomo sapiens (human)
positive regulation of attachment of mitotic spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
positive regulation of mitotic cytokinesisAurora kinase BHomo sapiens (human)
positive regulation of telomere cappingAurora kinase BHomo sapiens (human)
positive regulation of lateral attachment of mitotic spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
mitotic spindle organizationAurora kinase BHomo sapiens (human)
regulation of cytokinesisAurora kinase BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (69)

Processvia Protein(s)Taxonomy
protein kinase activityAurora kinase AHomo sapiens (human)
protein serine/threonine kinase activityAurora kinase AHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityAurora kinase AHomo sapiens (human)
protein bindingAurora kinase AHomo sapiens (human)
ATP bindingAurora kinase AHomo sapiens (human)
protein kinase bindingAurora kinase AHomo sapiens (human)
ubiquitin protein ligase bindingAurora kinase AHomo sapiens (human)
histone H3S10 kinase activityAurora kinase AHomo sapiens (human)
protein heterodimerization activityAurora kinase AHomo sapiens (human)
protein serine kinase activityAurora kinase AHomo sapiens (human)
molecular function activator activityAurora kinase AHomo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
RNA endonuclease activitySerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
platelet-derived growth factor receptor bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
enzyme bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
Hsp70 protein bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
protein homodimerization activitySerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
ADP bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
Hsp90 protein bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
unfolded protein bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
magnesium ion bindingRibosomal protein S6 kinase alpha-5Homo sapiens (human)
protein serine/threonine kinase activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
protein tyrosine kinase activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
protein bindingRibosomal protein S6 kinase alpha-5Homo sapiens (human)
ATP bindingRibosomal protein S6 kinase alpha-5Homo sapiens (human)
histone H3S10 kinase activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
histone H3S28 kinase activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
histone H2AS1 kinase activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
protein serine kinase activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
magnesium ion bindingRibosomal protein S6 kinase alpha-4Homo sapiens (human)
protein serine/threonine kinase activityRibosomal protein S6 kinase alpha-4Homo sapiens (human)
ribosomal protein S6 kinase activityRibosomal protein S6 kinase alpha-4Homo sapiens (human)
protein bindingRibosomal protein S6 kinase alpha-4Homo sapiens (human)
ATP bindingRibosomal protein S6 kinase alpha-4Homo sapiens (human)
histone H3S10 kinase activityRibosomal protein S6 kinase alpha-4Homo sapiens (human)
histone H3S28 kinase activityRibosomal protein S6 kinase alpha-4Homo sapiens (human)
protein serine kinase activityRibosomal protein S6 kinase alpha-4Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase Fes/FpsHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase Fes/FpsHomo sapiens (human)
protein bindingTyrosine-protein kinase Fes/FpsHomo sapiens (human)
ATP bindingTyrosine-protein kinase Fes/FpsHomo sapiens (human)
microtubule bindingTyrosine-protein kinase Fes/FpsHomo sapiens (human)
immunoglobulin receptor bindingTyrosine-protein kinase Fes/FpsHomo sapiens (human)
phosphatidylinositol bindingTyrosine-protein kinase Fes/FpsHomo sapiens (human)
protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
protein bindingProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
ATP bindingProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
protein phosphatase bindingProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
long-chain fatty acid transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
protein bindingSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
kinase bindingSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
dehydroascorbic acid transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
identical protein bindingSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
D-glucose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
protein kinase activityLeukocyte tyrosine kinase receptorHomo sapiens (human)
protein tyrosine kinase activityLeukocyte tyrosine kinase receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityLeukocyte tyrosine kinase receptorHomo sapiens (human)
protein bindingLeukocyte tyrosine kinase receptorHomo sapiens (human)
ATP bindingLeukocyte tyrosine kinase receptorHomo sapiens (human)
receptor signaling protein tyrosine kinase activator activityLeukocyte tyrosine kinase receptorHomo sapiens (human)
protein tyrosine kinase activityNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
growth hormone receptor bindingNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
protein bindingNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
ATP bindingNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
type 1 angiotensin receptor bindingNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
actin bindingFocal adhesion kinase 1Homo sapiens (human)
protein tyrosine kinase activityFocal adhesion kinase 1Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityFocal adhesion kinase 1Homo sapiens (human)
protein tyrosine phosphatase activityFocal adhesion kinase 1Homo sapiens (human)
integrin bindingFocal adhesion kinase 1Homo sapiens (human)
protein bindingFocal adhesion kinase 1Homo sapiens (human)
ATP bindingFocal adhesion kinase 1Homo sapiens (human)
JUN kinase bindingFocal adhesion kinase 1Homo sapiens (human)
protein kinase bindingFocal adhesion kinase 1Homo sapiens (human)
protein phosphatase bindingFocal adhesion kinase 1Homo sapiens (human)
SH2 domain bindingFocal adhesion kinase 1Homo sapiens (human)
molecular function activator activityFocal adhesion kinase 1Homo sapiens (human)
chromatin binding5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein serine/threonine kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
AMP-activated protein kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cAMP-dependent protein kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein binding5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
ATP binding5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
metal ion binding5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
tau protein binding5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
tau-protein kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein serine kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
histone H2BS36 kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PAK 2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein tyrosine kinase activator activitySerine/threonine-protein kinase PAK 2Homo sapiens (human)
small GTPase bindingSerine/threonine-protein kinase PAK 2Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase PAK 2Homo sapiens (human)
cadherin bindingSerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PAK 2Homo sapiens (human)
calmodulin-dependent protein kinase activityProtein-tyrosine kinase 2-betaHomo sapiens (human)
protein tyrosine kinase activityProtein-tyrosine kinase 2-betaHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityProtein-tyrosine kinase 2-betaHomo sapiens (human)
protein bindingProtein-tyrosine kinase 2-betaHomo sapiens (human)
ATP bindingProtein-tyrosine kinase 2-betaHomo sapiens (human)
ubiquitin protein ligase bindingProtein-tyrosine kinase 2-betaHomo sapiens (human)
glutamate receptor bindingProtein-tyrosine kinase 2-betaHomo sapiens (human)
3-phosphoinositide-dependent protein kinase bindingProtein-tyrosine kinase 2-betaHomo sapiens (human)
protein-containing complex bindingProtein-tyrosine kinase 2-betaHomo sapiens (human)
neurotransmitter receptor regulator activityProtein-tyrosine kinase 2-betaHomo sapiens (human)
protein serine/threonine kinase activityMaternal embryonic leucine zipper kinaseHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityMaternal embryonic leucine zipper kinaseHomo sapiens (human)
calcium ion bindingMaternal embryonic leucine zipper kinaseHomo sapiens (human)
protein bindingMaternal embryonic leucine zipper kinaseHomo sapiens (human)
ATP bindingMaternal embryonic leucine zipper kinaseHomo sapiens (human)
lipid bindingMaternal embryonic leucine zipper kinaseHomo sapiens (human)
protein serine kinase activityMaternal embryonic leucine zipper kinaseHomo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase BRSK2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase BRSK2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase BRSK2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase BRSK2Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase BRSK2Homo sapiens (human)
tau protein bindingSerine/threonine-protein kinase BRSK2Homo sapiens (human)
tau-protein kinase activitySerine/threonine-protein kinase BRSK2Homo sapiens (human)
ATPase bindingSerine/threonine-protein kinase BRSK2Homo sapiens (human)
ATPase regulator activitySerine/threonine-protein kinase BRSK2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase BRSK2Homo sapiens (human)
protein serine/threonine kinase activityAurora kinase BHomo sapiens (human)
protein serine/threonine kinase activityAurora kinase BHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityAurora kinase BHomo sapiens (human)
protein bindingAurora kinase BHomo sapiens (human)
ATP bindingAurora kinase BHomo sapiens (human)
kinase bindingAurora kinase BHomo sapiens (human)
protein serine kinase activityAurora kinase BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (86)

Processvia Protein(s)Taxonomy
spindle microtubuleAurora kinase AHomo sapiens (human)
nucleusAurora kinase AHomo sapiens (human)
nucleoplasmAurora kinase AHomo sapiens (human)
centrosomeAurora kinase AHomo sapiens (human)
centrioleAurora kinase AHomo sapiens (human)
spindleAurora kinase AHomo sapiens (human)
cytosolAurora kinase AHomo sapiens (human)
postsynaptic densityAurora kinase AHomo sapiens (human)
microtubule cytoskeletonAurora kinase AHomo sapiens (human)
basolateral plasma membraneAurora kinase AHomo sapiens (human)
midbodyAurora kinase AHomo sapiens (human)
spindle pole centrosomeAurora kinase AHomo sapiens (human)
ciliary basal bodyAurora kinase AHomo sapiens (human)
germinal vesicleAurora kinase AHomo sapiens (human)
axon hillockAurora kinase AHomo sapiens (human)
pronucleusAurora kinase AHomo sapiens (human)
perinuclear region of cytoplasmAurora kinase AHomo sapiens (human)
mitotic spindleAurora kinase AHomo sapiens (human)
meiotic spindleAurora kinase AHomo sapiens (human)
mitotic spindle poleAurora kinase AHomo sapiens (human)
glutamatergic synapseAurora kinase AHomo sapiens (human)
spindle pole centrosomeAurora kinase AHomo sapiens (human)
chromosome passenger complexAurora kinase AHomo sapiens (human)
spindle midzoneAurora kinase AHomo sapiens (human)
kinetochoreAurora kinase AHomo sapiens (human)
nuclear inner membraneSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
mitochondrionSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
endoplasmic reticulumSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
endoplasmic reticulum membraneSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
Ire1 complexSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
AIP1-IRE1 complexSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
IRE1-TRAF2-ASK1 complexSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
IRE1-RACK1-PP2A complexSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
nucleusRibosomal protein S6 kinase alpha-5Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-5Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-5Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-5Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-5Homo sapiens (human)
nucleusRibosomal protein S6 kinase alpha-4Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-4Homo sapiens (human)
cytosolRibosomal protein S6 kinase alpha-4Homo sapiens (human)
synapseRibosomal protein S6 kinase alpha-4Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-4Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-4Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
cytoplasmic vesicleTyrosine-protein kinase Fes/FpsHomo sapiens (human)
cytoplasmTyrosine-protein kinase Fes/FpsHomo sapiens (human)
Golgi apparatusTyrosine-protein kinase Fes/FpsHomo sapiens (human)
cytosolTyrosine-protein kinase Fes/FpsHomo sapiens (human)
focal adhesionTyrosine-protein kinase Fes/FpsHomo sapiens (human)
cytoplasmic side of plasma membraneTyrosine-protein kinase Fes/FpsHomo sapiens (human)
microtubule cytoskeletonTyrosine-protein kinase Fes/FpsHomo sapiens (human)
plasma membraneTyrosine-protein kinase Fes/FpsHomo sapiens (human)
membraneProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
receptor complexProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
plasma membraneProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
Golgi membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
female germ cell nucleusSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
photoreceptor inner segmentSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
female pronucleusSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cytosolSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
caveolaSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
intercalated discSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
basolateral plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
Z discSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
midbodySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cortical actin cytoskeletonSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
sarcolemmaSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
melanosomeSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
extracellular exosomeSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
blood microparticleSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
presynapseSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transporter complexSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
basolateral plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
plasma membraneLeukocyte tyrosine kinase receptorHomo sapiens (human)
membraneLeukocyte tyrosine kinase receptorHomo sapiens (human)
receptor complexLeukocyte tyrosine kinase receptorHomo sapiens (human)
plasma membraneLeukocyte tyrosine kinase receptorHomo sapiens (human)
plasma membraneNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cytoplasmic side of plasma membraneNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
extrinsic component of plasma membraneNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
nucleusNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cytoplasmNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cytosolNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cytoskeletonNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
plasma membraneNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
interleukin-12 receptor complexNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
extracellular exosomeNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
interleukin-23 receptor complexNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cytosolNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
stress fiberFocal adhesion kinase 1Homo sapiens (human)
nucleusFocal adhesion kinase 1Homo sapiens (human)
cytoplasmFocal adhesion kinase 1Homo sapiens (human)
centrosomeFocal adhesion kinase 1Homo sapiens (human)
cytosolFocal adhesion kinase 1Homo sapiens (human)
cytoskeletonFocal adhesion kinase 1Homo sapiens (human)
plasma membraneFocal adhesion kinase 1Homo sapiens (human)
focal adhesionFocal adhesion kinase 1Homo sapiens (human)
cell cortexFocal adhesion kinase 1Homo sapiens (human)
ciliary basal bodyFocal adhesion kinase 1Homo sapiens (human)
intracellular membrane-bounded organelleFocal adhesion kinase 1Homo sapiens (human)
perinuclear region of cytoplasmFocal adhesion kinase 1Homo sapiens (human)
plasma membraneFocal adhesion kinase 1Homo sapiens (human)
focal adhesionFocal adhesion kinase 1Homo sapiens (human)
dendritic spineFocal adhesion kinase 1Homo sapiens (human)
cytoplasm5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
nucleus5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
nucleoplasm5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cytoplasm5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cytosol5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
apical plasma membrane5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
nuclear speck5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
axon5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
dendrite5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
nucleotide-activated protein kinase complex5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
neuronal cell body5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
chromatin5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
nucleus5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
nucleusSerine/threonine-protein kinase PAK 2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PAK 2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PAK 2Homo sapiens (human)
cytosolSerine/threonine-protein kinase PAK 2Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase PAK 2Homo sapiens (human)
cell-cell junctionSerine/threonine-protein kinase PAK 2Homo sapiens (human)
postsynaptic densitySerine/threonine-protein kinase PAK 2Homo sapiens (human)
secretory granuleSerine/threonine-protein kinase PAK 2Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase PAK 2Homo sapiens (human)
glutamatergic synapseSerine/threonine-protein kinase PAK 2Homo sapiens (human)
NMDA selective glutamate receptor complexProtein-tyrosine kinase 2-betaHomo sapiens (human)
nucleusProtein-tyrosine kinase 2-betaHomo sapiens (human)
cytoplasmProtein-tyrosine kinase 2-betaHomo sapiens (human)
cytosolProtein-tyrosine kinase 2-betaHomo sapiens (human)
cytoskeletonProtein-tyrosine kinase 2-betaHomo sapiens (human)
focal adhesionProtein-tyrosine kinase 2-betaHomo sapiens (human)
cell cortexProtein-tyrosine kinase 2-betaHomo sapiens (human)
postsynaptic densityProtein-tyrosine kinase 2-betaHomo sapiens (human)
lamellipodiumProtein-tyrosine kinase 2-betaHomo sapiens (human)
dendriteProtein-tyrosine kinase 2-betaHomo sapiens (human)
growth coneProtein-tyrosine kinase 2-betaHomo sapiens (human)
neuronal cell bodyProtein-tyrosine kinase 2-betaHomo sapiens (human)
cell bodyProtein-tyrosine kinase 2-betaHomo sapiens (human)
perinuclear region of cytoplasmProtein-tyrosine kinase 2-betaHomo sapiens (human)
apical dendriteProtein-tyrosine kinase 2-betaHomo sapiens (human)
Schaffer collateral - CA1 synapseProtein-tyrosine kinase 2-betaHomo sapiens (human)
presynapseProtein-tyrosine kinase 2-betaHomo sapiens (human)
glutamatergic synapseProtein-tyrosine kinase 2-betaHomo sapiens (human)
postsynaptic density, intracellular componentProtein-tyrosine kinase 2-betaHomo sapiens (human)
dendritic spineProtein-tyrosine kinase 2-betaHomo sapiens (human)
focal adhesionProtein-tyrosine kinase 2-betaHomo sapiens (human)
plasma membraneProtein-tyrosine kinase 2-betaHomo sapiens (human)
plasma membraneMaternal embryonic leucine zipper kinaseHomo sapiens (human)
cell cortexMaternal embryonic leucine zipper kinaseHomo sapiens (human)
membraneMaternal embryonic leucine zipper kinaseHomo sapiens (human)
cytoplasmMaternal embryonic leucine zipper kinaseHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase BRSK2Homo sapiens (human)
endoplasmic reticulumSerine/threonine-protein kinase BRSK2Homo sapiens (human)
centrosomeSerine/threonine-protein kinase BRSK2Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase BRSK2Homo sapiens (human)
distal axonSerine/threonine-protein kinase BRSK2Homo sapiens (human)
centrosomeSerine/threonine-protein kinase BRSK2Homo sapiens (human)
kinetochoreAurora kinase BHomo sapiens (human)
condensed chromosome, centromeric regionAurora kinase BHomo sapiens (human)
nucleusAurora kinase BHomo sapiens (human)
nucleoplasmAurora kinase BHomo sapiens (human)
spindleAurora kinase BHomo sapiens (human)
cytosolAurora kinase BHomo sapiens (human)
chromocenterAurora kinase BHomo sapiens (human)
microtubule cytoskeletonAurora kinase BHomo sapiens (human)
midbodyAurora kinase BHomo sapiens (human)
chromosome passenger complexAurora kinase BHomo sapiens (human)
mitotic spindle poleAurora kinase BHomo sapiens (human)
mitotic spindle midzoneAurora kinase BHomo sapiens (human)
kinetochoreAurora kinase BHomo sapiens (human)
spindle pole centrosomeAurora kinase BHomo sapiens (human)
spindle microtubuleAurora kinase BHomo sapiens (human)
spindle midzoneAurora kinase BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (297)

Assay IDTitleYearJournalArticle
AID390012Binding affinity to human SRC at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389544Binding affinity to human NDR2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389616Binding affinity to human PAK1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389576Binding affinity to human PLK4 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390055Binding affinity to human ZAP70 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390083Binding affinity to human CK1e at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390028Binding affinity to human FLT4 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390068Binding affinity to human FAK at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389624Binding affinity to human NEK2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389582Binding affinity to human CDK2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389555Binding affinity to human PHKG1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389550Binding affinity to human CAMK1G at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389588Binding affinity to human JNK1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389568Binding affinity to human CAMKK2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389623Binding affinity to human FUSED at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389603Binding affinity to human MAP3K4 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389609Binding affinity to human MST1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390064Binding affinity to human EPHB4 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID1629277Antiparasitic activity against bloodstream form of Trypanosoma brucei 221 infected in mouse VSMC assessed as parasitic proliferation at 1 uM after 48 hrs by luciferase reporter gene assay2016Bioorganic & medicinal chemistry, 10-01, Volume: 24, Issue:19
Discovery and antiparasitic activity of AZ960 as a Trypanosoma brucei ERK8 inhibitor.
AID389614Binding affinity to human SLK at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390036Binding affinity to human LTK at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389629Binding affinity to human TLK2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389543Binding affinity to human DMPK1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390077Binding affinity to human MLK3 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389622Binding affinity to human ULK3 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390051Binding affinity to human EGFR at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389546Binding affinity to human YANK3 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390076Binding affinity to human HH498 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID1876004Inhibition of aurora B kinase (unknown origin)2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID389051Binding affinity to human FES2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389611Binding affinity to human MST3 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389608Binding affinity to human TNIK at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390005Binding affinity to human BMX at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389559Binding affinity to human AMPKA1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389560Binding affinity to human AMPKA2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390058Binding affinity to human EPHA4 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389531Binding affinity to human PKCH at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389596Binding affinity to human CLK4 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390053Binding affinity to human ERBB4 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390045Binding affinity to human AXL at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390067Binding affinity to human EPHA1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390032Binding affinity to human PDGFRB at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389536Binding affinity to human RSK2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389619Binding affinity to human PAK4 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389056Binding affinity to human TYK22008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390056Binding affinity to human EPHA3 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389630Binding affinity to human AAK1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390016Binding affinity to human FRK at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389554Binding affinity to human CAMK2G at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID1474637Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Discovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth.
AID389545Binding affinity to human PDK1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389612Binding affinity to human YSK1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390018Binding affinity to human CSK at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389635Binding affinity to human ALK1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID1079808Antiprotozoal activity against chloroquine/mefloquine/pyrimethamine-resistant Plasmodium falciparum C235 assessed as growth inhibition after 72 hrs by SYBR Green dye-based fluorescence assay2014MedChemComm, May-01, Volume: 5, Issue:5
Repurposing human Aurora kinase inhibitors as leads for anti-protozoan drug discovery.
AID1079807Antiprotozoal activity against chloroquine-resistant Plasmodium falciparum W2 assessed as growth inhibition after 72 hrs by SYBR Green dye-based fluorescence assay2014MedChemComm, May-01, Volume: 5, Issue:5
Repurposing human Aurora kinase inhibitors as leads for anti-protozoan drug discovery.
AID389610Binding affinity to human MST2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390010Binding affinity to human LCK at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389617Binding affinity to human PAK3 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389542Binding affinity to human MRCKA at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390021Binding affinity to human FGFR2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390057Binding affinity to human EPHA5 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389557Binding affinity to human MNK2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389577Binding affinity to human DAPK3 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390039Binding affinity to human IGF1R at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390037Binding affinity to human ROS at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390049Binding affinity to human ACK at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390047Binding affinity to human TYRO3 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390065Binding affinity to human EPHA8 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID1876092Antiviral activity against influenza A virus2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID390019Binding affinity to human FER at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID1629276Antiparasitic activity against bloodstream form of Trypanosoma brucei 221 infected in mouse VSMC assessed as reduction in log10 RLU at 1 uM after 48 hrs by luciferase reporter gene assay2016Bioorganic & medicinal chemistry, 10-01, Volume: 24, Issue:19
Discovery and antiparasitic activity of AZ960 as a Trypanosoma brucei ERK8 inhibitor.
AID389574Binding affinity to human PLK3 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390060Binding affinity to human EPHA7 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID1079806Antiprotozoal activity against chloroquine-resistant Plasmodium falciparum C2B assessed as growth inhibition after 72 hrs by SYBR Green dye-based fluorescence assay2014MedChemComm, May-01, Volume: 5, Issue:5
Repurposing human Aurora kinase inhibitors as leads for anti-protozoan drug discovery.
AID1741600Inhibition of recombinant human full-length His-tagged Aurora B expressed in baculovirus expression system using 5-FAM-LRRASLG-CONH2 as substrate preincubated for 60 mins followed by substrate addition by microfluidic assay2020European journal of medicinal chemistry, Oct-01, Volume: 203Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression.
AID389280Binding affinity to human PKCA at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389998Binding affinity to human TGFBR1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390073Binding affinity to human LIMK2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389590Binding affinity to human JNK2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390080Binding affinity to human RIPK2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390044Binding affinity to human MUSK at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390009Binding affinity to human LYN at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389579Binding affinity to human DRAK1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390031Binding affinity to human PDGFRA at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390066Binding affinity to human EPHA2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389628Binding affinity to human TLK1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389585Binding affinity to human ERK1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390024Binding affinity to human FGFR4 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389533Binding affinity to human MSK1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389047Binding affinity to human AMPKA12008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389621Binding affinity to human PAK6 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390084Binding affinity to human CK1gamma1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID740386Inhibition of NH3-AU1 epitope-tagged recombinant Trypanosoma brucei AUK1 expressed in procyclic form trypanosome AnTat1.1 assessed as decrease in myelin basic protein phosphorylation at 500 nM preincubated for 5 mins by pull down assay in presence of [gam2013European journal of medicinal chemistry, Apr, Volume: 62The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing.
AID389595Binding affinity to human CLK1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389534Binding affinity to human MSK2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389540Binding affinity to human PKG1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID273715Inhibition of Aurora-B immunoprecipitated from mitotic cells2006Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3
Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors.
AID389620Binding affinity to human PAK5 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389999Binding affinity to human BMPR1A at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390029Binding affinity to human FMS at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390079Binding affinity to human RAF1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389615Binding affinity to human LOK at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390088Binding affinity to human ADCK3 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389636Binding affinity to human ALK2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390020Binding affinity to human FES at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390048Binding affinity to human MET at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389046Binding affinity to human MSK22008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389552Binding affinity to human CAMK2D at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390042Binding affinity to human TRKC at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390062Binding affinity to human EPHB2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390002Binding affinity to human ABL at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389600Binding affinity to human CK2A1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389558Binding affinity to human STK33 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389613Binding affinity to human MST4 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390013Binding affinity to human YES at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389548Binding affinity to human CAMK1A at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389569Binding affinity to human CAMKK1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390059Binding affinity to human EPHA6 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390075Binding affinity to human TESK1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390008Binding affinity to human HCK at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389099Binding affinity to human AKT2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389565Binding affinity to human QIK at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390089Binding affinity to human ADCK4 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389632Binding affinity to human GAK at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389602Binding affinity to human MAP3K5 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390038Binding affinity to human INSR at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID706706Inhibition of human Aurora kinase B/INCEP complex expressed in Escherichia coli BL21 (DE3) using gamma-[32P]ATP incubated for 1 hr by autoradiography2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Crystal structure of human aurora B in complex with INCENP and VX-680.
AID390070Binding affinity to human JAK2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389634Binding affinity to human MYT1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389605Binding affinity to human KHS2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390071Binding affinity to human JAK1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389572Binding affinity to human AURB at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390035Binding affinity to human ALK at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID1079811Antiprotozoal activity against Plasmodium falciparum D6 assessed as growth inhibition after 72 hrs by SYBR Green dye-based fluorescence assay2014MedChemComm, May-01, Volume: 5, Issue:5
Repurposing human Aurora kinase inhibitors as leads for anti-protozoan drug discovery.
AID389597Binding affinity to human CLK2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389606Binding affinity to human HPK1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390017Binding affinity to human BRK at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390000Binding affinity to human ACTR2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389584Binding affinity to human PCTAIRE1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390041Binding affinity to human TRKB at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389592Binding affinity to human P38B at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390007Binding affinity to human ITK at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389604Binding affinity to human KHS1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389601Binding affinity to human CK2A2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389591Binding affinity to human P38A at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389045Binding affinity to human MSK12008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390069Binding affinity to human PYK2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389637Binding affinity to human ALK4 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389048Binding affinity to human BRSK22008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390082Binding affinity to human CK1d at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390003Binding affinity to human ARG at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390033Binding affinity to human FLT3 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390015Binding affinity to human FGR at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389537Binding affinity to human RSK4 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389050Binding affinity to human PAK22008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID1079812Antiprotozoal activity against intracellular amastigote stage of Leishmania major infected in mouse RAW246.7 cells assessed as growth inhibition after 96 hrs by luciferase reporter gene assay2014MedChemComm, May-01, Volume: 5, Issue:5
Repurposing human Aurora kinase inhibitors as leads for anti-protozoan drug discovery.
AID389547Binding affinity to human YANK2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389573Binding affinity to human AURA at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390040Binding affinity to human IRR at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID273716Reduction in mitotic histone H3 phosphorylation2006Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3
Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors.
AID389553Binding affinity to human CAMK2B at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389598Binding affinity to human CLK3 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389539Binding affinity to human PKACB at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390023Binding affinity to human FGFR1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389627Binding affinity to human NEK7 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID1876146Cytotoxicity against MDCK cells2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1079815Antiprotozoal activity against Trypanosoma brucei 427 assessed as growth inhibition after 48 hrs by PrestoBlue-based fluorescence assay2014MedChemComm, May-01, Volume: 5, Issue:5
Repurposing human Aurora kinase inhibitors as leads for anti-protozoan drug discovery.
AID390086Binding affinity to human MPSK1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389570Binding affinity to human LKB1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389578Binding affinity to human DAPK2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390027Binding affinity to human FLT1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389593Binding affinity to human P38G at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390043Binding affinity to human TRKA at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389581Binding affinity to human SKMLCK at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390054Binding affinity to human SYK at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390001Binding affinity to human ACTR2B at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389580Binding affinity to human DRAK2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389587Binding affinity to human NLK at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389538Binding affinity to human PRKX at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390072Binding affinity to human TYK2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389594Binding affinity to human GSK3A at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389589Binding affinity to human JNK3 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389098Binding affinity to human AKT1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389625Binding affinity to human NEK9 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390061Binding affinity to human EPHB1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID706705Inhibition of Xenopus laevis Aurora kinase B/INCEP complex using gamma-[32P]ATP incubated for 1 hr by autoradiography2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Crystal structure of human aurora B in complex with INCENP and VX-680.
AID1079810Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay2014MedChemComm, May-01, Volume: 5, Issue:5
Repurposing human Aurora kinase inhibitors as leads for anti-protozoan drug discovery.
AID389556Binding affinity to human PHKG2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390034Binding affinity to human TIE2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390052Binding affinity to human ERBB2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390025Binding affinity to human RET at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390087Binding affinity to human TTK at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389567Binding affinity to human PIM2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID353620Inhibition of aurora B kinase2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Discovery and development of aurora kinase inhibitors as anticancer agents.
AID390081Binding affinity to human CK1a2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389561Binding affinity to human BRSK2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390014Binding affinity to human FYN at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID1079813Antiprotozoal activity against promastigote stage of Leishmania major assessed as growth inhibition after 44 hrs by AlamarBlue staining-based fluorescence assay2014MedChemComm, May-01, Volume: 5, Issue:5
Repurposing human Aurora kinase inhibitors as leads for anti-protozoan drug discovery.
AID390004Binding affinity to human BTK at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390046Binding affinity to human MER at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389626Binding affinity to human NEK6 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID1419655Inhibition of Xenopus laevis aurora B (60 to 361 residues)/INCENP2017European journal of medicinal chemistry, Nov-10, Volume: 140A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies.
AID390085Binding affinity to human CK1g2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389583Binding affinity to human CDK5 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389049Binding affinity to human KHS22008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389575Binding affinity to human PLK1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390063Binding affinity to human EPHB3 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389571Binding affinity to human AURC at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID706704Inhibition of human Aurora kinase A/TPX2 complex using gamma-[32P]ATP incubated for 1 hr by autoradiography2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Crystal structure of human aurora B in complex with INCENP and VX-680.
AID390006Binding affinity to human TXK at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389535Binding affinity to human RSK1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389551Binding affinity to human CAMK2A at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389566Binding affinity to human PIM1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389564Binding affinity to human MARK4 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389633Binding affinity to human GCN2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390078Binding affinity to human BRAF at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390011Binding affinity to human BLK at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389053Binding affinity to human ROS2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389100Binding affinity to human AKT3 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389541Binding affinity to human PKG2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389607Binding affinity to human HGK at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389586Binding affinity to human ERK2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390050Binding affinity to human TNK1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389562Binding affinity to human MARK2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389055Binding affinity to human PYK22008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389532Binding affinity to human PKN2 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389563Binding affinity to human MARK1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389549Binding affinity to human CAMK1D at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389052Binding affinity to human LTK2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389599Binding affinity to human SRPK1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389631Binding affinity to human BIKE at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390074Binding affinity to human LIMK1 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390026Binding affinity to human KDR at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390022Binding affinity to human FGFR3 at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID389054Binding affinity to human FAK2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID390030Binding affinity to human KIT at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1159587Biochemical screen of P. falciparum PK72016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159588Biochemical screen of P. falciparum CDPK42016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159589Biochemical screen of P. falciparum MAPK22016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159586Biochemical screen of P. falciparum PK62016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159585Biochemical screen of P. falciparum CDPK12016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1801919Kinase Assay from Article 10.1021/acschembio.5b00940: \\Structural and Functional Analysis of the Allosteric Inhibition of IRE1a with ATP-Competitive Ligands.\\2016ACS chemical biology, 08-19, Volume: 11, Issue:8
Structural and Functional Analysis of the Allosteric Inhibition of IRE1α with ATP-Competitive Ligands.
AID1345688Human aurora kinase B (Aurora kinase (Aur) family)2003The Journal of cell biology, Apr-28, Volume: 161, Issue:2
The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (56)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's22 (39.29)29.6817
2010's17 (30.36)24.3611
2020's17 (30.36)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (5.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other55 (94.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]